The health service and its hospitals are struggling every single day to mitigate the consequences of the Covid-19 pandemic. At the same time, there is an awareness that everyday life is waiting on the other side of the pandemic, and that cancer patients in particular need ongoing treatment improvements.
2cureX has a well-established collaboration with a number of reputable cancer hospitals in Europe with the ambition to clinically validate the IndiTreat® test in order to make it available for patients. There has long been a strong desire to include a major Swedish cancer hospital in the collaboration. It is therefore with great pleasure to announce that Skåne University Hospital has decided to join the collaboration. Skåne´s participation will strengthen the efforts to validate the clinical outcome of treatment according to IndiTreat test results and ensure an easier access for Swedish patients to individually tailored treatment.
Jakob Eberhard, Associate Professor, Department of Oncology, Skåne University Hospital and Principal Investigator at Lund University Cancer Center says: “Precision Medicine is a key tool to offer patients the most effective treatment and to avoid side effects of ineffective therapy. Functional Precision Medicine, to which IndiTreat® belongs, is an interesting and promising method. Both for patients who have exhausted the recommendations of the international treatment guidelines as well as for patients when the goal is to identify the best of guideline-listed treatment alternatives. We look forward to participate in the collaborative network”.
Henrik Harling, Chief Medical Officer comments: “Skåne University Hospital has an excellent reputation and a large population base. It is therefore of great importance to 2cureX that Skåne wants to join the collaboration. We regard this decision as an expression of the importance of the work for the cancer patients. We have no doubt that the cooperation will promote that Swedish patients suffering from advanced colorectal cancer will have a faster access to our test method”.
For more information about 2cureX:
Ole Thastrup, Chief Executive Officer
Telephone: +45 2211 5399
Svensk Kapitalmarknadsgranskning AB
Phone: +46 11 32 30 732
This information is information that 2cureX AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on April 2, 2020.
2cureX has developed the IndiTreat® (Individual Treatment) test. IndiTreat® establishes thousands of 3D micro-tumours that are similar to the patient’s tumour and identifies the treatment that most effectively kills the patient’s tumor. Immediately after the test, the patient can be offered the selected treatment.
IndiTreat® is being clinically validated in clinical studies in colorectal cancer, ovarian cancer, pancreatic cancer and preventive cancer medicine. The clinical programs are conducted at major cancer hospitals in Denmark, Germany and United Kingdom.
IndiTreat® is presently being introduced into the European market through an Early Access Program.
The aspiration is that IndiTreat® becomes a standard tool in Precision Medicine for cancer patients.
The company is listed at the Nasdaq First North Growth Market in Stockholm (symbol “2CUREX”).